bioMérieux has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of the VIDAS®B•R•A•H•M•S PCT™ (Procalcitonin) assay using the change ...

Good day, and welcome to the bioMérieux Fourth Quarter Sales and Full Year 2024 Results Conference Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to ...

Thermo Fisher Scientific, Inc., the world leader in serving science, announced it pioneered an innovative trial design that helped its license partners, Roche Diagnostics USA and bioMérieux, achieve ...

bioMerieux, a French pharmaceutical firm with a major operation in Durham, has received U.S. Food and Drug Administration approval to sell its infection risk test in the U.S. The product, called VIDAS ...

Investing.com -- bioMérieux on Thursday cut its full-year 2025 sales forecast after reporting a 25% decline in first-half net income, driven by a large impairment, even as sales and operating margins ...